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The change in left ventricular ejection fraction from prein-
tervention to predischarge was prospectively assessed in
3 3 patients with acute myocardial infarction . Within 12 h
of symptom onset (mean 6.3 ± 2.7 h), patients were
randomly assigned to a double-blind intracoronary infusion
of streptokinase, nitroglycerin, both streptokinase and ni-
troglycerin or conventional therapy without acute cardiac
catheterization . Treatment effects were also assessed in
prospectively defined angiographic subsets .
There was a significant interaction between streptoki-
nase and nitroglycerin (p < 0 .01), resulting in an increase
in ejection fraction of 3 .  percentage units in the combined
treatment arm (p < 0 .001) . Patients with collateral flow to
a totally obstructed infarct-related artery showed a signif-
Thrombolytic therapy is the treatment of choice for patients
with acute myocardial infarction who present within 3 h of
pain onset (1-3) . Whereas the time limit for benefit from
interventions in evolving infarction has been clearly defined
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icant improvement over those without collateral flow in the
streptokinase (5 .4 ± 2.5%) and streptokinase-nitroglycerin
(10 .6 ± 2 .7 %) arms, but not in the nitroglycerin arm . Time
to treatment did not influence the change in ejection
fraction . In patients with initial subtotal occlusion, throm-
bolytic therapy was of no short-term benefit because ejec-
tion fraction increased by 6% in all three intervention
arms.
These findings indicate that relatively late thrombolytic
therapy results in significant myocardial salvage in those
patients with collateralized total coronary occlusion . This
benefit is potentiated by concomitant nitroglycerin therapy .
(J Am Coll Cardiol 1 8  ;14
 58-64)
in experimental animals (4,5), it is still undefined in human
patients . Several studies (6-8) suggest that the efficacy of
thrombolytic therapy, as assessed by the change in left
ventricular function, is dependent on initial angiographic
status . Furthermore, it has been suggested ( ,10) that the
benefit of thrombolytic therapy can be enhanced by adjuvant
therapy . Therefore, we performed a prospective randomized
double-blind trial to assess the effects of intracoronary
streptokinase, intracoronary nitroglycerin or their combina-
tion, administered within 12 h of the onset of chest pain . The
main end point was change in ejection fraction in angio-
graphic subsets defined prospectively on the basis of results
of the Registry of the European Society of Cardiology (6)
and the First Mount Sinai-New York University Reperfusion
Trial ( ) . Patients were enrolled in three New York City
hospitals and followed up for a minimum of 2 years .
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Methods
Study design and patients . A two by two factorial design
was selected to detect any interaction between intracoronary
infusions of streptokinase and nitroglycerin
. We prospec-
tively assessed the influence of baseline angiographic status
in the patients in the intervention arms of the study as
follows  total versus subtotal occlusion of the infarct-related
artery, and presence or absence of collateral flow to the
infarct vessel (6) . The study protocol was approved by the
committees on human research in the participating institu-
tions .
All patients with suspected acute myocardial infarction
were screened in the participating hospitals . Patients <78
years of age were eligible if they presented within 12 h of the
onset of myocardial ischemic pain of ?30 min duration and
demonstrated either a new ST segment elevation or depres-
sion over 0 .1 mV persisting 0 .08 s after the J point or
pathologic Q waves in two contiguous leads of the screening
electrocardiogram (ECG) . Exclusion criteria have been pub-
lished elsewhere ( ) .
Treatment arms . After signing informed consent, pa-
tients were prospectively stratified according to duration of
pain ; Group A  <2 h, Group B  2 to 12 h . They were
randomly assigned to one of four treatment arms
  1) intra-
coronary infusion of streptokinase, 2,000 U/min ; 2) intracor-
onary infusion of nitroglycerin, 0 .01 mg/min; 3) combined
infusion of streptokinase, 2,000 U/min and nitroglycerin,
0.01 mg/min ; or 4) a control group receiving conventional
therapy without acute catheterization . A radionuclide ven-
triculogram at rest and a standard 12 lead ECG were
obtained before cardiac catheterization . In the three inter-
vention arms, aortic pressures were recorded before dye
injection
. Intracoronary drug infusions were double-blind
and were maintained for a minimum of 75 min . If recanali-
zation occurred, the intracoronary infusion was continued
for at least an additional 30 min to a maximum of 120 min .
Concomitant therapy . All patients underwent full antico-
agulant therapy with intravenous heparin followed by war-
farin for 3 months . Nitrates, calcium channel antagonists and
beta-adrenergic blockers were not administered routinely in
the first 72 h . Percutaneous transluminal coronary angio-
plasty or coronary artery bypass surgery was performed in
5% of the study patients before end point data acquisition .
End point radionuclide ventriculograms and a 12 lead ECG
were obtained on day 10 to 14 .
Technical aspects of data acquisition and evaluation .
Radionuclide ventriculography . Red blood cells labeled with
30 mCi of technetium-  m were injected using a modified in
vivo technique
(11) .
Ejection fraction was calculated from
the "best septal" left anterior oblique view by a semiauto-
mated various region of interest count method, applying a
background correction (12) . The preintervention and end
point studies of each patient were analyzed by the core
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laboratory in a side by side fashion
; the core laboratory was
unaware which study represented the pretreatment or end
point nuclear ventriculogram
. Change in ejection fraction
was expressed in ejection fraction percentage units . Repro-
ducibility of the core laboratory's analyses was assessed by
recycling 10% of the raw data . Intraclass correlation coeffi-
cients (13) in the recycled studies yielded reliabilities of 0
. 6
for both preintervention and end point ejection fraction
.
Coronary angiography .
The infarct-related coronary ar-
tery was classified as totally obstructed if there was com-
plete cessation of anterograde flow, or as patent if there was
any degree of anterograde filling beyond the culprit lesion
.
Collateral vessels were determined to be present if any
segment of the infarct-related artery filled in other than a
continuous anterograde fashion
. The extent of collateral
filling was not further graded
.
Electrocardiograms . The sum of R wave height and the
number of pathologic Q waves were assessed from precor-
dial leads V, to
V6
in patients who had anterior wall
infarction, and leads II, III and aVF in patients who had
inferior wall infarction .
Statistical analysis . This trial was analyzed by intention
to treat. Continuous variables were expressed as mean
values ± SD, except where SEM was used
. Differences in
the distribution of baseline variables among the four treat-
ment arms were compared using analysis of variance for
continuous variables and chi-square analysis for categorical
variables .
The null hypothesis that the average change in ejection
fraction was the same for the four treatment arms was tested
by analysis of covariance . All changes in ejection fraction
reported are adjusted changes derived from the analysis of
covariance (14) . The following were considered as possible
covariates   age, preintervention ejection fraction, infarct
location, prior myocardial infarction, preintervention use of
beta-blockers and duration of pain prior to infusion . In
addition, the number of diseased vessels was considered as
a possible covariate in the intervention groups
.
In the mortality analysis, age, preintervention heart rate
and ejection fraction were used as covariates .
Results
Patient profile. Of the 3, 62 patients with suspected
myocardial infarction who were screened, 551 met the
eligibility criteria . One hundred fifty-eight eligible patients
were not enrolled, primarily because they refused to partic-
ipate (n = 78) or because a complete study team was not
available (n = 54) . Thus, the study group comprised 3 3
patients;  7 were assigned to the streptokinase arm,    to the
nitroglycerin arm,  6 to the streptokinase-nitroglycerin arm
and 101 to the control arm . The intracoronary infusion was
incomplete as a result of death or profound hemodynamic
instability in 18 of the 2 2 patients in the intervention groups .
60
	
RENTROP ET AL .
LATE THROMBOLYSIS AND COLLATERAL FLOW
Table 1 . Baseline Variables and Duration and Dosage of
Intracoronary Therapy in the 3 3 Study Patients
*Values obtained only in the three intervention arms
. ± = mean
standard deviation .
There were no statistically significant differences in any
of the baseline variables among the four treatment arms
(Table 1) . The time interval from the onset of pain to the
beginning of intracoronary infusion ranged from 1 .8 to 13 .6
h. The prevalence of initial subtotal obstruction of the
infarct-related artery in patients who underwent interven-
tional angiography was 27% (73 of 272) ; collaterals vessels to
the infarct-related artery were seen before intervention in
33% of patients (66 of 1  ) with complete obstruction of the
infarct-related vessel and in 11% (8 of 72) of those with
subtotal obstruction (p < 0.001). Myocardial infarction was
confirmed by an increase in serum creatine kinase to an
abnormal level in  1% of the patients (358 of 3 3)
.
Acute response to intracoronary interventions . The acute
recanalization rate of totally occluded infarct-related arteries
was 60% (40 of 67) in the streptokinase arm, 63% (3  of 62)
in the streptokinase-nitroglycerin arm (p = NS) and 8% (5 of
65) in the nitroglycerin arm (p < 0 .01). Systolic blood
pressure decreased during the study drug infusion in the
nitroglycerin arm by 12
.1 ± 20.2 mm Hg, in the streptoki-
nase-nitroglycerin arm by 11.4 ± 1 .8 mm Hg and in the
streptokinase arm by 4 .8 ± 15 .6 mm Hg. The decrease was
greater in those patients treated with nitroglycerin alone or
in combination with streptokinase than in patients treated
with streptokinase alone (p < 0 .05) .
Primary end point data . Paired gated blood pool scans
suitable for analysis were available in 272 patients . The main
reasons for missing data were insufficient quality of at least
one of the studies (n = 45) or death before end point
measurements (n = 34) . There were no significant differ-
ences in the baseline variables listed in Table 1 between the
272 patients with paired gated blood pool studies and the 121
patients with incomplete ejection fraction data, except for
gender distribution . The prevalence of female gender was
significantly greater among patients with incomplete ejection
fraction data (30% [36 of 121] versus 20% [54 of 272],
respectively) (p < 0.03). The missing data points were
evenly distributed among the treatment arms . Baseline ejec-
tion fraction values were not significantly different (Table 2)
.
There was a significant correlation of preintervention
ejection fraction with change in ejection fraction . None of
the other baseline variables considered as covariates added
significantly to the prediction of change in ejection fraction,
including time, whether considered as the interval between
pain onset and infusion or by group (A [<2 h] versus B [2 to
12 h]) .
In the model used to assess the significance of the
changes in ejection fraction, all changes in ejection fraction
were adjusted for the preintervention value (Table 2) (14) .
There was a significant positive streptokinase-nitroglycerin
interaction (p = 0 .01) (Fig . 1) . The only significant improve-
ment in ejection fraction from preintervention to end point
Table 2. Ejection Fraction Before Intervention and at Study End Point and Change in Ejection
Fraction From Preintervention to End Point Study Adjusted for the Preintervention Value by
Treatment Arm*
*The change in ejection fraction is expressed in percentage units
. Change in ejection fraction was adjusted for
preintervention value (14) . NTG = intracoronary nitroglycerin
; SK = intracoronary streptokinase; SK-NTG =
intracoronary streptokinase plus nitroglycerin .
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Variables
Age (yr)
57 ± 10
Men (%) 77
Prior myocardial infarction (%)
15
Current infarct location (%)
Anterior
47
Inferior
47
Lateral 6
Infarct-related coronary artery (%)
Left anterior descending 4 
Left circumflex
16
Right 35
Left main
1
Extent of coronary artery disease* (%)
Single vessel 48
Double vessel
36
Triple vessel 16
Time to infusion* (h)
6 .3 ± 2 .7
Duration of infusion (min) 85 .3 ± 24 .5
Total dose of streptokinase* (U)
173' ± 53'
Total dose of nitroglycerin* (mg) 0 .85 ± 0 .22
Intraaortic systolic pressure* (mm Hg) 133 ± 2 
Ejection fraction (%) 46.6 ± 14 .8
Arm
Preintervention
End Point
Adjusted
Change
p Value
No.
Mean
SD
Mean SD Mean SD
SK
6  43 .0 11 .8 44 .4 12 .6 0 .7 1 .2 0 .5
SK-NTG 64 48 .5 15 .3 51 .  16 .2 3
. 
1 .2
<0 .001
NTG
72 47 .2 15 .5 45 .3 14 .5 -1 .7 1 .1 0.1
Control 67 46 .4 15 .  47 .5 16 .3
1 .1
1 .2
0.3
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Figure 1 . Change (A) in ejection fraction (expressed as the change
in percentage units) from preintervention to end point study ad-
justed for preintervention ejection fraction in the four treatment
arms. C = control (no intracoronary therapy) ; NTG = intracoronary
nitroglycerin ; SK = intracoronary streptokinase ; SK-NTG = intra-
coronary streptokinase plus nitroglycerin .
occurred in the streptokinase-nitroglycerin arm (p < 0.001)
(Table 2) . The only significant difference in the change in
ejection fraction among treatment arms was between the
streptokinase-nitroglycerin arm and the nitroglycerin arm
(p < 0 .001) .
In patients assigned to the intervention groups, treatment
effects were assessed by three pretreatment angiographic
subsets  
1) total occlusion of the infarct-related artery with
observed collateral flow (n = 52) ; 2) total occlusion of the
infarct-related artery without collateral flow (n =  0) ; and 3)
subtotal obstruction of the infarct-related artery without
collateral flow (n = 48) . The group of patients with collater-
alized subtotal obstruction (n = 8) was too small for analysis .
Among patients with collateralized total coronary occlu-
sion, only those in the streptokinase-nitroglycerin arm
showed a significant improvement in ejection fraction of
 .8 ± 2 .1 percentage units (p < 0 .001) (Table 3, Fig . 2) . In
this angiographic subset, the differences in the change in
ejection fraction between the streptokinase-nitroglycerin
arm and the other intervention arms were significant ; strep-
tokinase-nitroglycerin arm versus streptokinase arm, 8
.1 ±
2.8 percentage units (p < 0 .005) ; streptokinase-nitroglycerin
RENTROP ET AL .
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TREATMENT ARM SK SK - NTG NTG
Figure 2. Change (A) in ejection fraction (expressed as the change
in percentage units) from preintervention to end point study by
treatment arm in patients with total coronary occlusion of the
infarct-related artery before therapy .
Closed bars = collateral chan-
nels present ;
striped bars = no collateral channels . Abbreviations as
in Figure 1
.
arm versus nitroglycerin arm, 13 .6 ± 3 .1 percentage units
(p < 0 .001) .
Noncollateralized total coronary occlusion was associ-
ated with a significant decrease in ejection fraction in both
the streptokinase and nitroglycerin arms, but not in the
streptokinase-nitroglycerin arm .
Within each treatment arm, the effect of collateral status
on the change in ejection fraction was evaluated in patients
with total coronary occlusion (Fig . 2) . In the streptokinase-
nitroglycerin arm, the subset with collateral flow showed a
net ejection fraction improvement by 10 .6 ± 2.7 percentage
units over the subset without collateral flow (p < 0 .001)
(Table 3) . In the streptokinase arm, ejection fraction im-
proved by 5.4 ± 2.5 percentage units in patients with
collateral flow over those without (p = 0
.03). In the nitro-
glycerin arm, there was no significant collateral effect
.
Subtotal obstruction of the infarct-related vessel was
associated with a significant improvement in ejection frac-
tion of about 6% in all three intervention arms ; there were no
significant differences among treatment arms (Table 3) .
Secondary end point data . Twelve lead electrocardio-
grams . Patients with anterior wall infarction in the streptoki-
Table 3.
Change in Ejection Fraction (in percentage units) From Preintervention to End Point
Study by Treatment Arm and Angiographic Subset
Ejection fraction change is significantly different from zero with the following p values   *<0.05, t<0 .01, t<0 .001 .
Abbreviations as in Table 2 .
Infarct
Artery
Obstruction
Collateral
Vessel
SK-NTG SK NTG
No . Mean SEMNo . Mean SEM No . Mean SEM
Total
Yes 18   .8 2 .1 t 20 1 .7 1 .  14 -3 .8 2 .3
Total No 25 -0 .8 1 .7 30 -3 .7 1 .6* 35 -5 .0 1 .5#
Subtotal
No 17 6 .0 2 .1t 16 6 .6 2 .2t 15 5 .7 2 .2t
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Table 4. Electrocardiographic Change From Preintervention to
End Point Study in Patients With Anterior Wall Infarction by
Treatment Arm
A. Sum of R Wave Amplitude, Leads V, to V
6
(mm)
Change is significantly different from zero with the following p values  
*<0 .001, t<0 .0001 . Abbreviations as in Table 2 .
nase-nitroglycerin arm showed beneficial treatment effects
because they experienced neither the significant loss of R
wave sum nor the increase in the number of Q waves from
baseline to end point studies that occurred in the other
treatment arms (Table 4) . With inferior wall infarction, no
treatment effects were found ; all treatment arms demon-
strated a significant decrease in R wave sum and increase in
the number of pathologic Q waves .
Mortality . Mortality did not differ significantly among
treatment arms at end point study (streptokinase, 3 of  7 ;
streptokinase-nitroglycerin, 3 of  6 ; nitroglycerin, 5 of    ;
control, 5 of 101) or at 2 years after enrollment (streptokinase,
12 of  6 ; streptokinase-nitroglycerin, 16 of  5 ; nitroglycerin,
14 of  7; control, 1  of    ; 6 patients lost to follow-up study) .
The  % (15 of 158 patients) in-hospital mortality rate for
patients who were eligible but not randomized did not differ
significantly from that observed in randomized patients .
Discussion
Trial design . In this trial, therapy was delayed l to 2 h to
gather nuclear and angiographic baseline data . Conse-
quently, the number of patients treated within <3 h of
symptom onset is too small to analyze the effects of early
thrombolytic therapy . Other investigators (7) utilized early
postintervention left ventriculograms in lieu of preinterven-
tion studies . However, we previously demonstrated (15) that
improvement in left ventricular function can occur immedi-
ately after reperfusion . Lack of paired ejection fraction data
in almost one-third of the randomized patients, which is
common in trials of comparable design (16), could have
influenced the observed changes in ejection fraction . How-
ever, patients with complete and incomplete ejection frac-
tion data differed only in gender distribution, a difference
JACC Vol . 14, No . I
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unlikely to influence the change in ejection fraction . The
intracoronary rather than the intravenous route of streptoki-
nase infusion was selected because of its higher recanaliza-
tion rates and its requisite angiographic documentation of
baseline coronary anatomy and recanalization (17) . Recom-
binant tissue-type plasminogen activator (rt-PA) was not
available at the time of our study ; however, we achieved
remarkably similar recanalization rates (18). The requisite
preintervention angiography in the present trial provides
insights into the pathophysiology of acute myocardial infarc-
tion, which can no longer be obtained . Furthermore, our
findings lead to hypotheses about the therapeutic potential of
second generation thrombolytic agents administered >3 h
after symptom onset .
Streptokinase-nitroglycerin interaction . The positive in-
teraction between streptokinase and nitroglycerin that re-
sulted in significant improvement in ejection fraction in
patients assigned to combined therapy is a major new finding
of this study . The ECG data support this finding   salvage of
myocardium as evidenced by greater preservation of R
waves and less development of Q waves occurred only in
those patients with anterior wall infarction who were as-
signed to combined therapy .
There are at least two possible mechanisms for the
beneficial effect of the addition of nitroglycerin to throm-
bolytic therapy . Although the dose of nitroglycerin infused
into the infarct-related artery was low, there was a systemic
effect, with a significant decrease in systolic blood pressure
and thus, in myocardial oxygen demand. Furthermore, it has
been established that nitroglycerin can increase collateral
flow (1 -21) . Such hemodynamic and collateral flow effects
could have decreased the rate of myocardial necrosis, result-
ing in greater myocardial salvage when reperfusion was
effected by thrombolytic therapy .
Angiographic subsets . Our results indicate that treatment
effects are highly dependent on prospectively defined angio-
graphic baseline variables . In patients with noncollateralized
total coronary occlusion, there was a lack of improvement in
ejection fraction regardless of treatment assignment, indicat-
ing that in this angiographic subset, meaningful myocardial
salvage is not possible if thrombolytic therapy is initiated
>3 h after coronary closure. This finding parallels data from
the animal model (4,5) in which reperfusion >3 h after abrupt
coronary closure did not result in significant myocardial
salvage .
Patients with collateralized total coronary occlusion had
the greatest potential for benefit
. There was a significant
increase of   .8 percentage units in ejection fraction with
assignment to the streptokinase-nitroglycerin arm, suggest-
ing that collateral flow extends the "time window" for
thrombolytic therapy, particularly when nitroglycerin is ad-
ministered concomitantly. The dramatic difference between
the observed increase in ejection fraction in the streptoki-
nase-nitroglycerin arm and the decrease of 3 .8 percentage
SK
SK-NTG
NTG
Control
40
33
36
3 
28
2 
30
24
21
18
21
1 
-8 . 
-4 .2
-10 . 
-10 .0
2 .1 ,
2 .3
2 .2t
2 .1 t
B . Number of Pathologic Q Waves
. Leads V, to V
6
(mm)
SK 40 1 .6 1 .6 1 .0
0 .3
SK-NTG 33 2 .0 1.7 0.4 0 .3
NTG 37 1 .  2 .1 0. 
0 .3*
Control
40 2 .4 1 .  1 .0 0 .3t
Preintervention Change
Arm n Mean SD Mean SEM
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units in the nitroglycerin arm indicates that the favorable
effects of nitroglycerin on the rate of necrosis are not of
value unless timely reperfusion is achieved
.
The improvement in left ventricular ejection fraction seen
in patients with collateral flow and in those with initial
subtotal obstruction indicates functional recovery of stunned
myocardium in both angiographic subsets . On the basis of
retrospective studies, it has been suggested (6,8) that resid-
ual flow through a subtotal lesion extends the time window
for myocardial salvage by thrombolytic therapy in a similar
way as does residual flow through collateral channels . How-
ever, improvement in left ventricular function has also been
observed in patients with subtotal obstruction who did not
receive thrombolytic therapy, albeit in a noncontrolled study
(7) .
Our study confirms this finding and shows that in this
angiographic subset, recovery of function is not augmented
by thrombolytic therapy . This finding is compatible with the
hypothesis that patients with initial subtotal obstruction
experienced spontaneous reperfusion before baseline angi-
ography, and that at the time of intervention, coronary flow
at rest was no longer critically impaired by either fibrin-
containing thrombus or spasm (22) .
Conclusions . Although experimental (4,5) and some clin-
ical data (1) suggest that the time limit for myocardial salvage
by reperfusion is <6 h after coronary occlusion, improve-
ment in ejection fraction has been demonstrated in patients
treated up to 18 h after pain onset in observational studies
(6,8,23) . Two large randomized studies (24,25) showed a
survival benefit from thrombolytic therapy initiated up to
24 h after symptom onset . The mechanism for a benefit from
late thrombolytic therapy has remained unclear. Our data
indicate that the presence of collateral flow to a totally
occluded coronary vessel slows the progression of myoc, , r-
dial necrosis . Because benefit from thrombolytic therapy aid
not decrease between 3 and 12 h after symptom onset,
myocardial necrosis may be incomplete for at least 12 h in
patients with collateral flow .
Collateralized total coronary occlusion was seen in about
25% of the patients in both our trials ( ), whereas almost half
of the patients had noncollateralized total occlusion . Thus,
the mortality benefit of late thrombolytic therapy would be
expected to be smaller than that of early treatment
. Demon-
stration of this mortality benefit would require a sample size
much larger than that in the present trial (25) .
Augmentation of ejection fraction benefit by intracoro-
nary nitroglycerin indicates that further evaluation of adju-
vant therapy with agents that decrease the rate of myocardial
necrosis is warranted .
We are indebted to Thomas Chalmers, MD for suggesting the two by two
factorial trial design, as well as to the members of the Safety and Data
Monitoring Committee for their guidance in the conduct of the trial and their
review of the manuscript
.
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Appendix
The Second Mount Sinai-New York University Reperfusion Trial in-
cluded the following participants 
Steering Committee  K. Peter Rentrop, MD (Chairman), Frederick Feit,
MD (Secretary), Warren Sherman, MD, Arthur Fox, MD, Richard Gorlin,
MD, Kenneth McKusick, MD, Arlie Cameron, MD, Stanley Goldsmith . MD,
Mariano Rey, MD
.
Clinical Units, Principal Investigators
 
Mount Sinai Medical Center, New
York, New York  
K
. Peter Rentrop, MD (Principal Investigator), Marc Cohen,
MD. John Ambrose, MD, Heinrich Blanke, MD, Barry Cohen, MD, Mark
Milner, MD, Jeffrey Cowen, MD, Rohit Arora, MD, Stephen Winters, MD,
Robert Phillips, MD, Robert Reichstein, MD, Robert Levine, MD, Rao
Betina, MD, Susan Hosat, MS ; Bellevue Hospital, New York, New York  
Frederick Feit, MD (Principal Investigator), Peter Stecy, MD, Mariano Rey,
MD, Mark Nachamie, MD, William Cole, MD, Frank Politzer, MD, Jeffrey
Kramer, MD, Mark Ehrich, MD, Gary Friedman, MD, Stephan Siegel, MD,
Frank Prior, MD, Michael Attubato, MD, James Slater, MD, Aaron Gindea,
MD, Sharon Napoli, RN, Susan Harty, RN, Virginia Bernardin, RN ; City
Hospital, Elmhurst, New York  Warren Sherman, MD (Principal Investiga-
tor), Richard Schneider, MD (former Principal Investigator), Robert Perdon-
cin, MD, William Schwartz, MD, Francis Lane, MD, Hee Lee, MD, R . Patel,
MD, Naomi Hill, RN .
Data Coordinating Center  John Thornton, PhD (Principal Investigator) .
Ford Calhoun . PhD, Harry Smith Jr, PhD, Richard Fagerstrom, PhD, Jim
Holt, MS, Lainy Berkowitz-Rudolph, RN, Jean Fisher, PhD, Mark Van
Buskirk, MS, Gail McAvay, MS .
Radionuclide Ventriculography Core Laboratory   Harvard University
School of Medicine, Boston, Massachusetts
  Kenneth McKusick, MD (Prin-
cipal Investigator), Tsunehiro Yasuda, MD .
Angiography Core Laboratory   St
. Luke's Hospital, New York, New
York   Arlie Cameron, MD (Principal Investigator), Harvey Kemp, MD
.
Electrocardiography Core Laboratory   New York University Hospital
School of Medicine, New York, New York   Mariano Rey, MD (Principal
Investigator) .
Thallium Scintigraphy Core Laboratory   Mount Sinai and New York
University Schools of Medicine, New York, New York   Stanley Goldsmith,
MD (Principal Investigator), Joseph Sanger . MD, Stephen Horowitz, MD,
Mary Farrell .
Hematology Core Laboratory  Mount Sinai Medical Center, New York,
New York   Jacob kand, MD (Principal Investigator) .
Safety and Data Monitoring Committee   William B . Hood, Jr, MD
(Chairman), Lewis C . Becker, MD, Paul Canner, PhD, Jay H . Cohn, MD .
Max Halperin, PhD, Thomas Killip 111, MD, Victor J . Marder, MD, Elliot
Rapaport, MD, Harmon Smith, PhD
. Thomas L . Robertson, MD (Ex Officio
Member) .
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